Evidence map›Paper›PMID 26403370›Full record

ArticleVaccine2015

Vaxvec: The first web-based recombinant vaccine vector database and its data analysis.

Shunzhou Deng, Carly Martin, Rasika Patil, Felix Zhu, Bin Zhao, Zuoshuang Xiang, Yongqun He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Shunzhou DengDepartment of Veterinary Medicine, Jiangxi Agricultural University, Nanchang, Jiangxi 330045, China; Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Carly MartinCollege of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI 48109, USA.
Rasika PatilCollege of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI 48109, USA.
Felix ZhuCollege of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI 48109, USA.
Bin ZhaoUnit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA; School of Information, University of Michigan, Ann Arbor, MI 48109, USA.
Zuoshuang XiangUnit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Yongqun HeUnit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Center for Computational Medicine and Biology, University of Michigan, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: yongqunh@med.umich.edu.
University of Michigan–Ann Arbor · USJiangxi Agricultural University · CN

Funding

Ontology-based Information Network to Support Vaccine ResearchR01AI081062 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HE, YONGQUN · 2009 to 2012
$1.1M
NIAID NIH HHS R01 AI081062NIAID NIH HHS R01AI081062
6 · The paper itself

Abstract

A recombinant vector vaccine uses an attenuated virus, bacterium, or parasite as the carrier to express a heterologous antigen(s). Many recombinant vaccine vectors and related vaccines have been developed and extensively investigated. To compare and better understand recombinant vectors and vaccines, we have generated Vaxvec (http://www.violinet.org/vaxvec), the first web-based database that stores various recombinant vaccine vectors and those experimentally verified vaccines that use these vectors. Vaxvec has now included 59 vaccine vectors that have been used in 196 recombinant vector vaccines against 66 pathogens and cancers. These vectors are classified to 41 viral vectors, 15 bacterial vectors, 1 parasitic vector, and 1 fungal vector. The most commonly used viral vaccine vectors are double-stranded DNA viruses, including herpesviruses, adenoviruses, and poxviruses. For example, Vaxvec includes 63 poxvirus-based recombinant vaccines for over 20 pathogens and cancers. Vaxvec collects 30 recombinant vector influenza vaccines that use 17 recombinant vectors and were experimentally tested in 7 animal models. In addition, over 60 protective antigens used in recombinant vector vaccines are annotated and analyzed. User-friendly web-interfaces are available for querying various data in Vaxvec. To support data exchange, the information of vaccine vectors, vaccines, and related information is stored in the Vaccine Ontology (VO). Vaxvec is a timely and vital source of vaccine vector database and facilitates efficient vaccine vector research and development.

Indexed as

Databases, FactualDatabases, GeneticDrug CarriersGenetic VectorsAnimalsHumansInternetVaccines, SyntheticDrug CarriersVaccines, SyntheticBioinformaticsDatabaseRecombinant vaccine vectorRecombinant vector vaccineVaccineVaxvec

Identifiers

PMID26403370
PMCPMC4679550
OpenAlexW1894620164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.